ONCONEXT RISK

ONCONEXT RISKTM includes Genoma Group’s tests dedicated to the study of germline mutations, present in all the cells of the individual and transmissible to offspring, which are firmly believed to be involved in hereditary tumor development.

The studied mutations are mutations localized on genes that codify for proteins with the role of tumor suppressors (negative control of cell proliferation, DNA repairing and apoptosis regulation) and that limit their biological function.

Carriers of these mutations have higher predisposition of developing tumor pathologies.

Following daily exposure to mutagenic factors, tumor suppression activities could be compromised, more favourably than the general population, leaving free to act potential tumor suppressor genes (function of cell cycle progression and cell proliferation) deriving from proto oncogenes, also triggered by the exposure to mutagenic agents.

OncoNext-Risk-OncoScreening-Relazione-Tecnica

Technical report
Onconext Risk

I test

ONCONEXT RISKTM Tests are performed by a peripheral blood sample in EDTA, and it’s sufficient a sample of 3-5 ML.

DOWNLOAD ONCONEXT RISK TM BROCHURE DEDICATED TO PROFESSIONAL

risk-brochure-onconext

ASK FOR MORE INFORMATION ABOUT THE TEST

Name (required)



Email (required)



Choose the type of test you require



Message



 I have read and accept Privacy Policy